Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Corrigendum
Current Issue
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letters to Editor
Literature Review
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Corrigendum
Current Issue
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letters to Editor
Literature Review
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
View/Download PDF

Translate this page into:

Letter to the Editor
34 (
1
); 94-95
doi:
10.4103/ijn.ijn_103_23

An Adolescent with Tuberous Sclerosis and Hypocalcemia and a Renal Mass

Pediatric Nephrology, Kidney Institute, Medanta, The Medicity, Gurgaon, India
Urology Institute, Medanta, The Medicity, Gurgaon, India, Gurgaon, Haryana, India
Pediatric Neurology, PGIMER Chandigarh, Chandigarh, Punjab, India
Department of Pathology and Laboratory Medicine, Medanta, The Medicity, Gurgaon, Haryana, India
Kidney Institute, Medanta, The Medicity, Gurgaon, Haryana, India

Corresponding Author: Dr. Sidharth Kumar Sethi, Pediatric Nephrology, Kidney Institute, Medanta, The Medicity, Gurgaon - 122 001, Haryana, India. E-mail: sidsdoc@gmail.com

Licence
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Sethi SK, Nataraj SA, Sankhyan N, Rana A, Nair A, Bansal SB. An Adolescent with Tuberous Sclerosis and Hypocalcemia and a Renal Mass. Indian J Nephrol 2024;34:94-5. doi: 10.4103/ijn.ijn_103_23

Dear Editor,

A 13-year-old girl, a known case of tuberous sclerosis, presented with complaints of paresthesias for the last one year and documented severe hypocalcemia (serum calcium 5.5 mg/dl). She had a history of multiple episodes of myoclonic seizures since the last 10 years, which was being managed with multiple anti-epileptic drugs, namely, valproic acid, lamotrigine, and lacosamide. Her surgical history revealed a left frontal craniotomy with near-total excision of subependymal giant cell astrocytoma (2016; at age seven). Her laboratory parameters are listed in Table 1, and MRI scans are shown in Figure 1a. Contrast-enhanced MRI axial imaging of kidneys showed a T1 hypointense and T2 hyperintense exophytic heterogeneously enhancing mass arising from medial cortex of the lower pole of the right kidney. Cystic lesions were seen as hypointense lesions in the remaining visualized parenchyma. Axial short tau inversion recovery (STIR) image showed a heterogeneous mass with multiple internal hyperintense areas that were suggestive of necrosis.

Table 1: Laboratory parameters at admission
Blood Values at presentation Reference range
Serum calcium 5.5 mg/dl 8.4–10.2 mg/dl
Serum parathyroid hormone 906.3 pg/ml 15.0–68.3 pg/ml
25-hydroxyvitamin D 16.6 ng/ml 20–40 ng/ml
Serum phosphorus 6.8 mg/dl 2.5–4.5 mg/dl
Blood urea 24 mg/dl 15–36 mg/dl
Serum creatinine 0.50 mg/dl 0.7–1.2 mg/dl
Serum uric acid 3.9 mg/dl 2.5–6.2 mg/dl
Serum sodium 141 mmol/L 137–145 mmol/L
Serum potassium 3.5 mmol/L 3.5–5.1 mmol/L
Hemoglobin 11.5 g/dl 12–15 g/dl
Serum albumin 2.6 g/dl 3.5–5 g/dl
(a) Contrast-enhanced MRI axial image of kidneys. There is a T1 hypointense and T2 hyperintense exophytic heterogeneously enhancing mass arising from the medial cortex of the lower pole of the right kidney. Cystic lesions are seen as hypointense lesions in the remaining visualized parenchyma. Axial short tau inversion recovery image shows a heterogeneous mass with multiple internal hyperintense areas suggestive of necrosis. (b) Papillary pattern composed of cells with abundant eosinophilic cytoplasm and hyperchromatic irregular nuclei with punctate nucleoli. Hob-nailing of cells is also seen focally.
Figure 1:
(a) Contrast-enhanced MRI axial image of kidneys. There is a T1 hypointense and T2 hyperintense exophytic heterogeneously enhancing mass arising from the medial cortex of the lower pole of the right kidney. Cystic lesions are seen as hypointense lesions in the remaining visualized parenchyma. Axial short tau inversion recovery image shows a heterogeneous mass with multiple internal hyperintense areas suggestive of necrosis. (b) Papillary pattern composed of cells with abundant eosinophilic cytoplasm and hyperchromatic irregular nuclei with punctate nucleoli. Hob-nailing of cells is also seen focally.

The child received intravenous calcium gluconate and oral 1,25-vitamin D supplements to rapidly raise serum calcium. The child also received weekly 25-hydroxyvitamin D supplementation. The valproate dose was reduced based on the serum levels (126 mcg/ml; normal range 50–100 mcg/ml). The mass lesion revealed papillary renal cell carcinoma [Figure 1b]. Right open partial nephrectomy was performed. The child’s serum calcium and the need for oral calcium and active vitamin D supplement reduced over the next two weeks. Currently, at a follow-up of six months, the child is doing well, having a normal serum creatinine of 0.6 mg/dl, and is on RDA supplement of oral calcium.

Tuberous sclerosis (TSC) is caused by germline loss-of-function mutations of either the TSC1 or TSC2 gene. Approximately 60% of germline TSC gene mutations are de novo and 40% are inherited. TSC is a multisystemic neurocutaneous disorder affecting the brain (subependymal giant cell astrocytomas, cerebral cortical tubers), heart (rhabdomyomas), kidney (angiomyolipomas, cysts, renal cell carcinomas), lung (lymphangioleiomyomatosis [LAM]), and skin (angiofibromas). TSC patients can also develop seizures, autism, and cognitive disability.1

Hypocalcemia is a serious medical condition in patients with TSC who develop seizures and are on anti-epileptic drugs, namely, valproic acid, which increases degradation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 by upregulation of 24-hydroxylase CYP24A causing inhibitory effects on calcium absorption and end-organ resistance and inhibition of calcitonin secretion.2

The renal manifestations of TSC include angiomyolipomas, epithelial cysts which can resemble polycystic kidney disease, and renal cell carcinoma (RCC). Angiomyolipomas are the most frequent lesion (75%) followed by simple renal cysts (17%).1,2 Around 4% of patients develop RCC.25 Careful morphological studies of such RCC have permitted their subdivision into groups: clear cell (most common); others being papillary, chromophobe and unclassified RCC, and benign renal cell oncocytoma.3,4 Tumors in TSC, including angiomyolipomas and RCCs, develop after somatic “second hit” inactivation of the remaining wild-type allele of TSC1 or TSC2.5

RCC, though rare, should be kept in mind as a differential diagnosis when encountering a TSC patient with renal mass, even in children. Regular radiological surveillance may help in early detection and timely intervention to decrease renal morbidity and mortality.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms.

Conflicts of interest

There are no conflicts of interest.

Financial support and sponsorship

Nil.

References

  1. , . Renal Tumors in Tuberous sclerosis complex. Pediatr Nephrol. 2021;36:1427-38.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , . Severe hypocalcemia in a patient with tuberous sclerosis complex. Electrolyte Blood Press. 2019;17:21-4.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol. 2014;38:895-909.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. Tuberous sclerosis-associated renal cell carcinoma: A clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol. 2014;38:1457-67.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , . Renal cell carcinoma in tuberous sclerosis complex. Genes (Basel). 2021;12:1585.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
252

PDF downloads
84
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections